This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IVERIC bio Yönetim

Yönetim kriter kontrolleri 2/4

IVERIC bio CEO'su Glenn Sblendorio, Jul2017 tarihinde atandı, in görev süresi 6.17 yıldır. in toplam yıllık tazminatı $ 9.82M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.1% maaş ve 92.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.17% ine doğrudan sahiptir ve bu hisseler € 8.69M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.5 yıl ve 4.6 yıldır.

Anahtar bilgiler

Glenn Sblendorio

İcra Kurulu Başkanı

US$9.8m

Toplam tazminat

CEO maaş yüzdesi	7.1%
CEO görev süresi	6yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	5.5yrs
Yönetim Kurulu ortalama görev süresi	4.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Glenn Sblendorio'un ücretlendirmesi IVERIC bio'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2023	n/a	n/a	-US$223m
Dec 31 2022	US$10m	US$700k	-US$185m
Sep 30 2022	n/a	n/a	-US$159m
Jun 30 2022	n/a	n/a	-US$141m
Mar 31 2022	n/a	n/a	-US$122m
Dec 31 2021	US$6m	US$665k	-US$115m
Sep 30 2021	n/a	n/a	-US$107m
Jun 30 2021	n/a	n/a	-US$108m
Mar 31 2021	n/a	n/a	-US$96m
Dec 31 2020	US$4m	US$640k	-US$85m
Sep 30 2020	n/a	n/a	-US$77m
Jun 30 2020	n/a	n/a	-US$66m
Mar 31 2020	n/a	n/a	-US$61m
Dec 31 2019	US$2m	US$599k	-US$59m
Sep 30 2019	n/a	n/a	US$63m
Jun 30 2019	n/a	n/a	US$62m
Mar 31 2019	n/a	n/a	US$64m
Dec 31 2018	US$1m	US$625k	US$63m
Sep 30 2018	n/a	n/a	-US$51m
Jun 30 2018	n/a	n/a	US$153m
Mar 31 2018	n/a	n/a	US$144m
Dec 31 2017	US$3m	US$560k	US$114m
Sep 30 2017	n/a	n/a	US$57m
Jun 30 2017	n/a	n/a	-US$192m
Mar 31 2017	n/a	n/a	-US$200m
Dec 31 2016	US$9m	US$373k	-US$193m

Tazminat ve Piyasa: Glenn 'nin toplam tazminatı ($USD 9.82M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.59M ).

Tazminat ve Kazançlar: Glenn şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Glenn Sblendorio (67 yo)

6yrs

Görev süresi

US$9,816,150

Tazminat

Mr. Glenn P. Sblendorio, M.B.A., served as the President of IVERIC bio, Inc. (formerly, Ophthotech Corporation) since February 1, 2017 until May 01, 2021 and has been its Chief Executive Officer since July...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Glenn Sblendorio	CEO & Director	6yrs	US$9.82m	0.17% € 8.7m
Pravin Dugel	President & Director	2.2yrs	US$4.63m	0.15% € 7.4m
David Carroll	Senior VP	6.3yrs	US$2.68m	0.032% € 1.6m
Keith Westby	Senior VP & COO	6.5yrs	US$2.66m	0.029% € 1.4m
Christopher Simms	Senior VP & Chief Commercial Officer	1.9yrs	US$2.67m	0.024% € 1.2m
Samir Patel	Co-Founder and Consultant	16.5yrs	Veri yok	Veri yok
Xiao-Ping Dai	Chief Technical Officer	2.5yrs	Veri yok	Veri yok
Kathy Galante	Senior VP of Investor Relations & Corporate Communications	no data	Veri yok	Veri yok
Todd Anderman	Senior VP	5.4yrs	Veri yok	Veri yok
Amy Sheehan	Senior VP & Chief Human Resources Officer	5.5yrs	Veri yok	Veri yok
Evelyn Harrison	Senior VP & Chief Clinical Operations Officer	7.5yrs	US$411.67k	Veri yok
Guangping Gao	Chief Strategist of Gene Therapy	3.7yrs	Veri yok	Veri yok

5.5yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: O2T 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Glenn Sblendorio	CEO & Director	6.2yrs	US$9.82m	0.17% € 8.7m
Pravin Dugel	President & Director	less than a year	US$4.63m	0.15% € 7.4m
Axel Bolte	Independent Director	15.9yrs	US$354.59k	0.016% € 801.9k
Adrienne Graves	Independent Chairman of the Board	4.6yrs	US$398.34k	0.016% € 801.9k
Mark Blumenkranz	Independent Director	3yrs	US$354.59k	0.023% € 1.2m
Carl Regillo	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Calvin Roberts	Independent Director	4.5yrs	US$365.84k	0.034% € 1.7m
Jane Pritchett Henderson	Independent Director	5.5yrs	US$385.84k	0.016% € 801.9k
Anat Lowenstein	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jeffrey Heier	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Peter Kaiser	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Adnan Tufail	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

4.6yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: O2T 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.6 yıldır).

This company listing is no longer active

IVERIC bio Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Iveric Bio Announces the Addition of Pravin U. Dugel to Its Board of Directors

Independent Director recently bought €231k worth of stock

IVERIC bio, Inc., Annual General Meeting, May 12, 2022

Recent updates

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from NASDAQ Composite Index

IVERIC bio's Common Stock Delisted from NASDAQ

Forecast to breakeven in 2025

Forecast to breakeven in 2025

No longer forecast to breakeven

Forecast to breakeven in 2025

IVERIC bio, Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Iveric Bio Announces the Addition of Pravin U. Dugel to Its Board of Directors

Forecast to breakeven in 2025

Iveric Bio, Inc. Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy

IVERIC bio, Inc. has completed a Follow-on Equity Offering in the amount of $300.375 million.

IVERIC bio, Inc. Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy

IVERIC bio, Inc. Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

IVERIC bio, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Iveric Bio Announces Positive Topline Data from Zimura® Gather2 Phase 3 Clinical Trial in Geographic Atrophy

IVERIC bio, Inc. to Report Q2, 2022 Results on Jul 26, 2022

Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® At American Society of Retina Specialists Meeting

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Microcap Value Index

Independent Director recently bought €231k worth of stock

IVERIC bio, Inc. Announces Presentation of Post-Hoc Analysis At Macula Society from Gather1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

IVERIC bio, Inc. Completes Retrospective Review of Choroidal Neovascularization

IVERIC bio, Inc., Annual General Meeting, May 12, 2022

IVERIC bio, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

IVERIC bio, Inc. Announces in GATHER2, the Company's Phase 3 Clinical Trial Evaluating the Safety and Efficacy of Zimura (Avacincaptad Pegol) for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration

IVERIC Bio, Inc. Provides Updates on Clinical Trails

IVERIC bio, Inc. Updates on Its Phase 3 Clinical Trails Zimura

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş